Janux Therapeutics (JANX) Payables (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Payables data on file, last reported at $3.4 million in Q1 2026.

• On a quarterly basis, Payables rose 43.6% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $3.4 million, a 43.6% increase from a year earlier, with the FY2025 full-year figure at $5.0 million, up 23.47% from the prior year.
• Payables for Q1 2026 stood at $3.4 million, down from $5.0 million in the prior quarter.
• Over the last five years, Payables for JANX reached as high as $5.0 million in Q4 2025 and fell as low as $1.3 million in Q2 2024.
• Historically, Payables has averaged $2.7 million across 5 years, with a median of $2.5 million in 2024.
• Across the five-year window, Payables jumped 747.46% in 2022 and plunged 36.33% in 2023, its largest moves.
• Year by year, Payables stood at $2.2 million in 2022, then increased by 12.27% to $2.4 million in 2023, then surged by 66.09% to $4.0 million in 2024, then increased by 23.47% to $5.0 million in 2025, then slumped by 32.09% to $3.4 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $3.4 million in Q1 2026, $5.0 million in Q4 2025, and $3.4 million in Q3 2025.